BriaCell Therapeutics Corp. (TSX:BCT)

BriaCell Therapeutics Income Statement

Financials in millions USD. Fiscal year is August - July.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jan 31, 2026	Jul 31, 2025	Jul 31, 2024	Jul 31, 2023	Jul 31, 2022	Jul 31, 2021
Selling, General & Admin	5.61	5.93	6.15	7.94	7.27	4.96
Research & Development	22.73	21.27	27.18	15.34	8.02	2.02
Total Operating Expenses	28.34	27.2	33.33	23.27	15.29	6.98
Operating Income	-28.34	-27.2	-33.33	-23.27	-15.29	-6.98
Other Non-Operating Income (Expense)	0.44	0.34	0.37	0.85	-11.55	-6.84
Total Non-Operating Income (Expense)	0.44	0.34	0.37	0.85	-11.55	-6.84
Pretax Income	-27.9	-26.87	-32.96	-22.42	-26.84	-13.82
Net Income	-27.54	-26.31	-4.79	-20.3	-26.84	-13.82
Minority Interest in Earnings	0.3	0.24	0.14	-	-	-
Net Income to Common	-27.54	-26.31	-4.79	-20.3	-26.84	-13.82
Shares Outstanding (Basic)	1	0	0	0	0	0
Shares Outstanding (Diluted)	1	0	0	0	0	0
Shares Change (YoY)	781.80%	285.70%	5.35%	0.81%	242.82%	533.09%
EPS (Basic)	-18.52	-62.19	-43.68	-195.00	-259.50	-459.00
EPS (Diluted)	-18.52	-62.19	-43.68	-195.00	-259.50	-459.00
Free Cash Flow	-26.8	-28.17	-24.58	-23.74	-12.48	-7.75
Free Cash Flow Per Share	-18.06	-66.58	-224.09	-228.03	-120.86	-257.22
EBITDA	-28.3	-27.1	-33.25	-23.26	-15.27	-6.96
EBIT	-28.34	-27.2	-33.33	-23.27	-15.29	-6.98

Updated Jan 31, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.